There’s always a certain energy at PDA Week – the kind that comes from a shared sense that our industry is moving, sometimes faster than we expect. This year in Denver, that energy felt different. More focused. More urgent. And in many ways, more practical.

As both an exhibitor and attendee representing Lachman Consultants, I had the opportunity to reconnect with long-standing clients, meet new innovators, and spend time in the sessions and roundtables that are shaping where pharmaceutical manufacturing is headed next.

One theme stood above the rest:

Artificial Intelligence is no longer a future consideration—it’s an operational reality.

From Curiosity to Commitment

Looking back at PDA Week 2025, the AI conversation was still exploratory. There was genuine curiosity, paired with appropriate caution. Sessions focused on foundational questions:

  • How do we validate AI in a GMP environment?
  • What are global regulators expecting?
  • Can large language models be used safely in quality systems?

The tone was thoughtful, but measured. AI was something to evaluate, pilot, and understand. Fast forward to 2026 and the shift is unmistakable and impossible to miss.

This year, AI wasn’t confined to a handful of sessions—it was embedded across the agenda. It showed up in contamination control discussions, environmental monitoring strategies, cleaning validation approaches, and even broader operational decision-making frameworks.

The conversation has moved from “Should we use AI?” to “How do we effectively integrate AI into systems that are already live and regulated?”

AI in the Real World of Good Manufacturing Practice

What stood out most in this year’s agenda, and in the conversations on the exhibit floor, was the level of specificity. The industry is no longer talking about abstract use cases. We’re seeing real applications.

  • Predictive models informing contamination-control strategies
  • AI-enabled environmental monitoring trending beyond traditional limits
  • Data-driven approaches to cleaning validation
  • Early signals of AI influencing visual inspection and defect detection paradigms

This is a meaningful evolution. AI is no longer sitting on top of the organization as an analytical tool, it’s being woven into the fabric of GMP operations.

The Regulatory Undercurrent

One of the most consistent threads throughout PDA Week was that regulators are watching industry closely. The question is no longer whether AI can be used in regulated environments—it’s whether organizations are using it responsibly, transparently, and in a way that enhances process understanding and control.

Many companies are advancing quickly on the technological side, but governance models, validation approaches, and lifecycle management strategies are still catching up. The gap between capability and control is narrowing, but it hasn’t closed.

What This Means for the Industry

If I had to summarize the shift in one sentence, it would be this: Pharma is moving from applying AI to existing systems to redesigning systems with AI in mind. That’s a fundamental change. It impacts how we think about data integrity, how we define state of control, how we approach investigations and deviations, and, ultimately, how we ensure consistent product quality.

Events such as this present the moments where ideas are tested, challenges are shared openly, and real progress begins. What stood out this year was how aligned many of our clients are in their thinking. While organizations may be at different stages of AI adoption, there is a shared recognition that the pace is accelerating and collaboration is essential.

Whether it’s integrating AI into quality systems, aligning with evolving regulatory expectations, or ensuring inspection readiness in a more data-driven environment, the goal is the same:

Turn innovation into something that works consistently, compliantly, and at scale.

Final Thoughts

It was a great week in Denver, full of insight, connection, and forward momentum. We’re grateful for the time spent with our clients and peers, and we’re looking forward to continuing these conversations in the months ahead.